Biological therapy for inflammatory bowel disease in children

So Young Na; Jung Ok Shim

doi:10.5223/pghn.2012.15.1.13

Biological therapy for inflammatory bowel disease in children

So Young Na, Jung Ok Shim

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

Original language	English
Pages (from-to)	13-18
Number of pages	6
Journal	Pediatric Gastroenterology, Hepatology and Nutrition
Volume	15
Issue number	1
DOIs	https://doi.org/10.5223/pghn.2012.15.1.13
Publication status	Published - 2012

Keywords

Children
Inflammatory bowel disease
Infliximab

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hepatology
Gastroenterology

Access to Document

10.5223/pghn.2012.15.1.13

Cite this

@article{368c311705a84819a106963604606e8d,

title = "Biological therapy for inflammatory bowel disease in children",

abstract = "The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.",

keywords = "Children, Inflammatory bowel disease, Infliximab",

author = "Na, {So Young} and Shim, {Jung Ok}",

note = "Publisher Copyright: {\textcopyright} 2014 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.",

year = "2012",

doi = "10.5223/pghn.2012.15.1.13",

language = "English",

volume = "15",

pages = "13--18",

journal = "Pediatric Gastroenterology, Hepatology and Nutrition",

issn = "2234-8646",

publisher = "Korean Society of Pediartic Gastroenterology, Hepatology and Nutrition",

number = "1",

}

TY - JOUR

T1 - Biological therapy for inflammatory bowel disease in children

AU - Na, So Young

AU - Shim, Jung Ok

PY - 2012

Y1 - 2012

N2 - The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

AB - The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

KW - Children

KW - Inflammatory bowel disease

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=84951969424&partnerID=8YFLogxK

U2 - 10.5223/pghn.2012.15.1.13

DO - 10.5223/pghn.2012.15.1.13

M3 - Review article

AN - SCOPUS:84951969424

SN - 2234-8646

VL - 15

SP - 13

EP - 18

JO - Pediatric Gastroenterology, Hepatology and Nutrition

JF - Pediatric Gastroenterology, Hepatology and Nutrition

IS - 1

ER -

Biological therapy for inflammatory bowel disease in children

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this